MedTrace Logo

Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation

NCT05256979 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-03-17

No results posted yet for this study

Summary

Patients with NAFLD indicated for ursodeoxycholic acid treatment ("by SPC: cholestatic hepatitis") will be offered an observational study. Examinations will be performed before the treatment and after 6month period. Laboratory parameters, non-invasive indices, liver elastography, cardiovascular parameters and liver MR spectroscopy will be performed.

Conditions

  • Non-Alcoholic Fatty Liver Disease

Sponsors & Collaborators

  • General University Hospital, Prague

    lead OTHER

Principal Investigators

  • Radan BRUHA, Prof. · General University Hospital, Prague

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-02
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05256979 on ClinicalTrials.gov